Novartis trial setback for del-desiran in myotonic dystrophy study
Novartis said a late-stage study of del-desiran in myotonic dystrophy did not meet a target on a key metric. The company reaffirmed its sales guidance through 2030.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.